Fibrosis regression induced by intravenous gammaglobulin treatment

被引:43
作者
Amital, H
Rewald, E
Levy, Y
Bar-Dayan, Y
Manthorpe, R
Engervall, P
Sherer, Y
Langevitz, P
Shoenfeld, Y [1 ]
机构
[1] Chaim Sheba Med Ctr, Dept Med B, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Autoimmune Dis Res Unit, IL-52621 Tel Hashomer, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[4] Fdn Hematol, Mar Del Plata, Argentina
[5] Malmo Univ Hosp, Dept Rheumatol, Sjogrens Syndrome Res Ctr, Malmo, Sweden
[6] Karolinska Hosp, Div Haematol, Dept Med, S-10401 Stockholm, Sweden
[7] Chaim Sheba Med Ctr, Dept Med F, IL-52621 Tel Hashomer, Israel
[8] Chaim Sheba Med Ctr, Rheumatol Unit, IL-52621 Tel Hashomer, Israel
关键词
D O I
10.1136/ard.62.2.175
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition. Methods: Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjogren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura. Results: Fibrotic excess was reduced in all the patients by IVIg treatment. In five patients the disease as a whole benefited from the infusion of immunoglobulins. Conclusion: IVIg may enhance resorption of fibrosis and promote healing in patients with fibrotic associated disorders.
引用
收藏
页码:175 / 177
页数:3
相关论文
共 16 条
[1]   Successful treatment of early secondary myelofibrosis in SLE with IVIG [J].
Aharon, A ;
Levy, Y ;
BarDayan, Y ;
Afek, A ;
ZandmanGoddard, G ;
Skurnik, Y ;
Fabrizzi, F ;
Shoenfeld, Y .
LUPUS, 1997, 6 (04) :408-411
[2]   SUPPRESSION OF CYTOKINE-DEPENDENT HUMAN T-CELL PROLIFERATION BY INTRAVENOUS IMMUNOGLOBULIN [J].
AMRAN, D ;
RENZ, H ;
LACK, G ;
BRADLEY, K ;
GELFAND, EW .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 73 (02) :180-186
[3]   The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice [J].
Blank, M ;
Levy, Y ;
Amital, H ;
Shoenfeld, Y .
ARTHRITIS AND RHEUMATISM, 2002, 46 (06) :1689-1690
[4]   SELECTIVE INDUCTION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST AND INTERLEUKIN-8 IN HUMAN MONOCYTES BY NORMAL POLYSPECIFIC IGG (INTRAVENOUS IMMUNOGLOBULIN) [J].
DESOUZA, VR ;
CARRENO, MP ;
KAVERI, SV ;
LEDUR, A ;
SADEGHI, H ;
CAVAILLON, JM ;
KAZATCHKINE, MD ;
HAEFFNERCAVAILLON, N .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (05) :1267-1273
[5]  
JAMES B, 2000, SEMIN HEMATOL, V37, P261
[6]  
Jelaska A, 1998, J CELL PHYSIOL, V175, P19, DOI 10.1002/(SICI)1097-4652(199804)175:1<19::AID-JCP3>3.0.CO
[7]  
2-F
[8]   Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - A preliminary report [J].
Levy, Y ;
Sherer, Y ;
Langevitz, P ;
Lorber, M ;
Rotman, P ;
Fabrizzi, F ;
Shoenfeld, Y .
CLINICAL RHEUMATOLOGY, 2000, 19 (03) :207-211
[9]  
MANTHORPE R, 1986, SCAND J RHEUMATOL, P19
[10]  
Rewald E, 1997, AM J HEMATOL, V54, P340